Target type: biologicalprocess
Any process that modulates the frequency, rate or extent of neutrophil activation. [GOC:TermGenie, PMID:17588661]
Neutrophil activation is a complex process tightly regulated by a intricate network of signaling pathways and molecular mechanisms. These pathways are initiated by a variety of stimuli, including bacterial products, inflammatory mediators, and complement components. Upon stimulation, neutrophils undergo a series of changes, including adhesion to the endothelium, migration to the site of inflammation, and release of cytotoxic substances. This complex process is regulated by a delicate balance between activating and inhibitory signals, which ensures that neutrophil function is appropriately controlled.
Activation of neutrophils is initiated by the engagement of surface receptors, such as TLRs, Fc receptors, and complement receptors. Engagement of these receptors triggers intracellular signaling cascades involving various kinases and adaptors, ultimately leading to the activation of transcription factors such as NF-kB and AP-1. These transcription factors, in turn, promote the expression of genes encoding for a variety of pro-inflammatory mediators, including chemokines, cytokines, and reactive oxygen species (ROS).
The production of ROS is a hallmark of neutrophil activation and plays a critical role in the killing of pathogens. ROS are generated by the NADPH oxidase enzyme complex, which is activated upon stimulation. ROS can damage bacterial membranes and DNA, contributing to their destruction.
Neutrophil activation is tightly regulated by a variety of inhibitory mechanisms that prevent excessive inflammation and tissue damage. These inhibitory mechanisms include the expression of negative regulators of signaling pathways, such as phosphatases and inhibitory receptors. Additionally, neutrophils express anti-inflammatory cytokines such as IL-10, which can suppress the inflammatory response.
The balance between activating and inhibitory signals is crucial for maintaining neutrophil homeostasis. Dysregulation of neutrophil activation can lead to a variety of inflammatory diseases, including autoimmune diseases and sepsis. Therefore, understanding the mechanisms that regulate neutrophil activation is essential for the development of new therapeutic strategies for these diseases.'
"
Protein | Definition | Taxonomy |
---|---|---|
Phospholipase A2, membrane associated | A phospholipase A2, membrane associated that is encoded in the genome of human. [PRO:DNx, UniProtKB:P14555] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
quinacrine | quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9. Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2. | acridines; aromatic ether; organochlorine compound; tertiary amino compound | antimalarial; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor |
nifedipine | Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. | C-nitro compound; dihydropyridine; methyl ester | calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent |
ubenimex | ubenimex: growth inhibitor | ||
5-benzyloxytryptophan | |||
fpl 67047xx | FPL 67047XX: inhibits phospholipase A2; structure in first source | ||
3-octylthio-1,1,1-trifluoro-2-propanone | 3-octylthio-1,1,1-trifluoro-2-propanone: a pesticide synergist; inhibits juvenile hormone esterase | ||
varespladib | aromatic ether; benzenes; dicarboxylic acid monoamide; indoles; monocarboxylic acid; primary carboxamide | anti-inflammatory drug; antidote; EC 3.1.1.4 (phospholipase A2) inhibitor | |
ly 311727 | LY 311727: a potent & selective inhibitor of human non-pancreatic secretory phospholipase A2; structure given in first source | ||
amentoflavone | biflavonoid; hydroxyflavone; ring assembly | angiogenesis inhibitor; antiviral agent; cathepsin B inhibitor; P450 inhibitor; plant metabolite | |
ochnaflavone | ochnaflavone : A biflavonoid with an ether linkage between the B-rings of the apigenin and luteolin subunits. It has been isolated from several members of the Ochnaceae plant family. ochnaflavone: from Lonicera japonica; structure given in first source | aromatic ether; biflavonoid; hydroxyflavone | anti-inflammatory agent; antiatherogenic agent; antibacterial agent; EC 3.1.1.4 (phospholipase A2) inhibitor; leukotriene antagonist; plant metabolite |
manoalide | manoalide : A sesterterpenoid isolated from the marine sponge Luffariella variabilis and which has been shown to exhibit inhibitory activity towards phospholipase A2. manoalide: phospholipase A2 inhibitor; sesterterpene from marine sponge L. variabilis; structure given in first source | butenolide; lactol; sesterterpenoid | EC 3.1.1.4 (phospholipase A2) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; metabolite |
ym 26734 | YM 26734: inhibits group II phospholipase A2; structure given in first source | ||
indoxam | indoxam: structure in first source | ||
bolinaquinone | bolinaquinone: a marine sesquiterpenoid from sponge Dysidea sp. with anti-inflammatory activity; structure in first source | ||
cacospongionolide b | cacospongionolide B: isolated from the sponge Fasciospongia cavernosa; structure in first source |